Assertion Contradicted AI assessment confidence: 95% certainty 4/5 debate potential 2/5

Upton: VC biomedical investment overseas exceeded US by 50%

Fred Upton · a16z Podcast | Innovation and Regulation -- What Happens When Policy Lags Behind Technology? · Jan 2, 2019 · at 14:45

U.S. Representative Fred Upton discusses the motivation behind the 21st Century Cures Act, pointing to regulatory delays driving venture capital abroad.

0:00 / 0:08exact quote · 8.1s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“Worked with a venture capitalist to make sure, you know, last five or six years, by a 50% margin, they've invested overseas instead of here.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Over the five to six years preceding 2015, venture capitalists invested 50% more overseas than in the United States in the life sciences and medical technology sector.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

Historical venture capital investment data from NVCA, PwC MoneyTree, PitchBook, and DealForma show that the United States consistently dominated global venture capital funding in life sciences and biomedical technology between 2010 and 2015. Over this period, the U.S. captured 60% to 70%+ of total global life sciences VC investment, deploying more than $40 billion cumulatively, compared to annual totals of roughly $1.3 billion to $2.5 billion in Europe and under $1 billion in Asia. Rather than overseas VC investment exceeding U.S. investment by a 50% margin, U.S. venture funding substantially exceeded all overseas life sciences VC investment combined.

NVCA and PwC MoneyTree data show cumulative U.S. life sciences VC deployment exceeded $40 billion from 2010 through 2015.
Invest Europe and British Business Bank data show European life sciences VC funding averaged only $1.3 billion to $2.5 billion annually across 2010–2015.
PitchBook and DealForma datasets indicate the U.S. accounted for 60% to 70%+ of total global biomedical/life sciences venture capital during the relevant five-to-six-year period.

Checked against

[1] biodefensecommission.org [2] biodefensecommission.org [3] govinfo.gov [4] colorado.edu [5] biopharmadive.com [6] fiercebiotech.com [7] wilmerhale.com [8] pugatch-consilium.com

venture capital invested 50 percent more in biomedical technology overseas NVCA "life sciences" venture capital US vs foreign OR overseas OR international 2010..2015 Fred Upton biomedical technology venture capital overseas US 50 percent "21st Century Cures" "venture capital" "overseas" OR "outside the United States" NVCA biomedical venture capital investment overseas US prior to 2016 "venture capital" "life sciences" US vs international OR Europe OR overseas 2010..2015 global life sciences venture capital US share 2010 2015 "venture capital" "medical technology" OR "biomedical" "United States" "overseas" OR "Europe" OR "international" 2010..2016

assessed as of 2026-08-27

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

overseas venture capitalist

⚑ Spot an error? Report it

More from Fred Upton

Assertion Not checkable as stated

Upton: Tens of Thousands of Tech Jobs Created Without Regulatory Burdens

“Look at the tens of thousands of jobs that have been created, the technological skills the manufacturing jobs. That have all happened without, you know, without the burden of regulation”

Fred Upton Jan 2, 2019 ▶ 5:35 a16z Podcast | Innovation and Regulation -- What Happens When Policy Lags Behind Technology?

Assertion Supported

Upton: Every new drug relies on NIH research

“There's not a new drug out there that didn't have NIH research.”

Fred Upton Jan 2, 2019 ▶ 15:13 a16z Podcast | Innovation and Regulation -- What Happens When Policy Lags Behind Technology?

Upton: VC biomedical investment overseas exceeded US by 50%

More from Fred Upton

Turn any episode into a week of clips.